ADVB
Advanced Biomed Inc.Company Information
- Company Name
- Advanced Biomed Inc.
- CIK
- CIK0001941029
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ADVB: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8071
- SIC Description
- Services-Medical Laboratories
- Ticker
- ADVB
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 31,602
- Shares outstanding
- 1,082,000
- Ownership
- 2.92%
Earnings Market Reaction
- Filing date
- 2026-05-15
- Price on filing date
- —
- 1-month reaction
- -5.23%
- 3-month reaction
- 81.82%
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | - | 0 | - | - | - | - | ||||||
Assets Current | ||||||||||||
| Cash | - | 3 | 3 | 3 | 5 | 3 | ||||||
| Cash And Cash Equivalents At Carrying Value | 3 | - | - | - | 3 | - | ||||||
| Prepaid Expense And Other Assets Current | 8 | 8 | 3 | 3 | 3 | 0 | ||||||
| Assets Current | 11 | 11 | 6 | 6 | 8 | 3 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | 0 | ||||||
| Deferred Costs | - | - | - | - | - | 1 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | 0 | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | - | - | ||||||
| Assets Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Assets | 11 | 11 | 6 | 7 | 8 | 5 | ||||||
Liabilities Current | ||||||||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 1 | 3 | 3 | 4 | 4 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 1 | 1 | 3 | 3 | 4 | 4 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 1 | 1 | 3 | 3 | 4 | 4 | ||||||
Stockholders Equity | ||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 22 | 21 | 21 | 21 | 21 | 16 | ||||||
| Retained Earnings Accumulated Deficit | -13 | -13 | -20 | -19 | -19 | -17 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Stockholders Equity | 9 | 9 | 3 | 3 | 4 | 1 | ||||||
| Liabilities And Stockholders Equity | 11 | 11 | 6 | 7 | 8 | 5 | ||||||
| Majority Shareholder | 0 | -0 | 0 | 0 | 0 | 0 | ||||||
| Corporate Joint Venture | -0 | -1 | 1 | 1 | 0 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | 20 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 1 | 1 | 20 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAdvanced Biomed Inc. (ADVB) — SEC Financial Statements & Analysis
Advanced Biomed Inc. (ADVB) is a services-medical laboratories company, incorporated in NV. Advanced Biomed Inc. trades on Nasdaq as: ADVB. Advanced Biomed Inc. (ADVB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-15. Based on that filing, Advanced Biomed Inc. carries a market cap of $5.86M, a P/E ratio of 1.17x, a P/B ratio of 0.64x, an enterprise value of $3.26M, and an EV/EBITDA multiple of 0.98x. On profitability, it posts a Return on Equity (ROE) of 75.19%, a Return on Assets (ROA) of 52.97%, and a Return on Invested Capital (ROIC) of 79.76%. Per share, it reports EPS of $3.90, diluted EPS of $3.90, free cash flow per share of $-2.29, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 7.38x, a quick ratio of 1.83x, working capital of $9.10M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.13, an interest coverage ratio of 26919.63x, free cash flow of $-2.94M (TTM), and net debt of $-2.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.86M
- P/E TTM
- 1.17x
- EPS TTM
- $3.90
- P/B TTM
- 0.64x
- ROE TTM
- 75.19%
- ROA TTM
- 52.97%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-2.94M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Advanced Biomed Inc. in?
Advanced Biomed Inc. (ADVB) operates in the Services-Medical Laboratories industry.
What exchange does ADVB trade on?
Advanced Biomed Inc. (ADVB) trades on the Nasdaq.
Where is Advanced Biomed Inc. incorporated?
Advanced Biomed Inc. is incorporated in NV.
When was Advanced Biomed Inc. (ADVB)'s most recent SEC filing?
Advanced Biomed Inc. (ADVB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-15.
What is ADVB's market cap?
Advanced Biomed Inc. (ADVB) has a market capitalization of $5.86M as of 2026-03-31.
What is ADVB's P/E ratio?
Advanced Biomed Inc. (ADVB)'s trailing twelve month P/E ratio is 1.17x as of 2026-03-31.
What is ADVB's EPS (earnings per share)?
Advanced Biomed Inc. (ADVB)'s trailing twelve month EPS is $3.90 as of 2026-03-31.
What is ADVB's ROE (return on equity)?
Advanced Biomed Inc. (ADVB)'s trailing twelve month Return on Equity (ROE) is 75.19% as of 2026-03-31.
What is ADVB's ROA (return on assets)?
Advanced Biomed Inc. (ADVB)'s trailing twelve month Return on Assets (ROA) is 52.97% as of 2026-03-31.
What is ADVB's ROIC (return on invested capital)?
Advanced Biomed Inc. (ADVB)'s trailing twelve month Return on Invested Capital (ROIC) is 79.76% as of 2026-03-31.
What is ADVB's EV/EBITDA?
Advanced Biomed Inc. (ADVB)'s trailing twelve month EV/EBITDA is 0.98x as of 2026-03-31.